Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Exelixis Inc

EXEL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: HOLD

Last Close

$51.24

▲ +1.24%

Market Cap $12.70B · Vol 683.18K

Key Metrics

P/E Ratio

16.09

FWD: 14.24

Market Cap

$12.70B

Large Cap

Div Yield

N/A

EPS Growth

+16.55%

YoY

RSI (14)

38.60

Momentum

Beta

0.40

vs Market

52W High

$57.56

10.98% below

52W Low

$33.76

51.80% above

Volume

683.18K

Avg 1.12M

P/B

5.32

Price-to-book

ROE

35.53%

Return on equity

Free Float

98.06%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Exelixis Inc (EXEL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EXEL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.23%

-8.12%

+0.27%

+16.67%

YTD

+16.91%

+33.19%

+137.66%

+180.31%

Financials & Valuation

TTM · Annual

Total Revenue	$2.32B
Net Income	$782.57M
Revenue Growth (YoY)	+10.63%
Gross Margin	96.39%
Operating Margin	38.48%
Net Profit Margin	33.73%
ROE	35.53%
ROA · ROIC	32.50% · 35.53%

P/E Ratio	16.09
Forward P/E (FY1)	14.24
PEG Ratio	0.27
P/S	5.32
P/B	5.32
P/FCF	14.11
EPS Growth	+16.55%
Outstanding Shares	247.78M

Technical Indicators

50-Day SMA	$54.14
200-Day SMA	$46.54
RSI (14)	38.60
Beta	0.40
52-Week High	$57.56
52-Week Low	$33.76

Volume Today	683.18K
Avg Daily Volume (30D)	1.12M
Relative Volume	0.61x
Volatility (10D)	54.18
Volatility (30D)	38.41
Free Float	98.06%

Analyst Consensus

HOLD

Current Price $51.24

Mean Target $53.01

52W Low$33.76 52W High$57.56

Current

Target

$33.76 $57.56

Current Analyst target

+3.46% upside potential · 20 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SD42W4

ISINUS30161Q1040

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.